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Background
Rhabdomyosarcoma is the most common soft tissue sarcoma in childhood and has a poor
prognosis. Here we assessed the capability of ex vivo expanded cytokine-induced killer cells to
lyse both alveolar and embryonic rhabdomyosarcoma cell lines and investigated the mecha-
nisms involved.
Design and Methods
Peripheral blood mononuclear cells from six healthy donors were used to generate and expand
cytokine-induced killer cells. The phenotype and composition of these cells were determined
by multiparameter flow cytometry, while their cytotoxic effect against rhabdomyosarcoma
cells was evaluated by a europium release assay.  
Results
Cytokine-induced killer cells efficiently lysed cells from both rhabdomyosarcoma cell lines.
Antibody-mediated masking of either NKG2D molecule on cytokine-induced killer cells or its
ligands on rhabdomyosarcoma cells (major histocompatibility antigen related chain A and B
and UL16 binding protein 2) diminished this effect by 50%, suggesting a major role for the
NKG2D molecule in rhabdomyosarcoma  cell killing. No effect was observed after blocking
CD11a, CD3 or TCRʱb molecules on cytokine-induced killer cells or CD1d on rhabdomyosar-
coma cells. Remarkably, cytokine-induced killer cells used tumor necrosis factor-related apop-
tosis-inducing ligand (TRAIL) to activate caspase-3, as the main caspase responsible for the exe-
cution of apoptosis. Accordingly, blocking TRAIL receptors on embryonic rhabdomyosarcoma
cell lines significantly reduced the anti-tumor effect of cytokine-induced killer cells. About 50%
of T cells within the cytokine-induced killer population had an effector memory phenotype,
20% had a naïve phenotype and approximately 30% of the cells had a central memory pheno-
type. In addition, cytokine-induced killer cells expressed low levels of activation-induced mark-
ers CD69 and CD137 and demonstrated a low alloreactive potential.
Conclusions
Our  data  suggest  that  cytokine-induced  killer  cells  may  be  used  as  a  novel  adoptive
immunotherapy for the treatment of patients with rhabdomyosarcoma after allogeneic stem cell
transplantation.  
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Rhabdomysarcoma  is  the  most  frequent  soft  tissue
tumor of childhood and accounts for 3-4% of all pediatric
cancers.
1 During  the  last  30  years  survival  rates  have
increased  as  a  result  of  multimodal  therapy  strategies.
However, the chance of cure is very low for patients with
primary  metastatic  or  relapsed  rhabdomyosarcoma  or
Ewing’s  tumors.
2-4 In  the  German  multicenter  studies
CWS-81, -86, -91 and-96, patients older than 10 years at
diagnosis with bone or bone marrow metastases had a 5-
year event-free survival of 2%.
5,6 There were no survivors
after relapse.
Allogeneic  stem  cell  transplantation  might  provide  a
graft-versus-tumor  effect,  and  successful  induction  and
maintenance of remission have been reported in patients
with solid tumors treated with such transplants.
7,8 To fur-
ther evaluate treatment using allogeneic stem cell trans-
plantation  we  started  a  prospective  study  in  high-risk
patients with rhabdomyosarcoma. Our preliminary data
show that patients undergoing transplantation while in
remission do have a realistic chance of being cured from
their disease,
9 suggesting that the graft-versus-tumor effect
may be of importance in the treatment of such tumors.
Additional novel cellular therapies should, therefore, be
further explored. 
Cytokine-induced  killer  (CIK)  cell  therapy  may
become  the  key  to  successful  treatment  of  rhab-
domyosarcoma. The ideal therapeutic approach would
be to generate CIK cells from the stem cell donor. CIK
cells  are  ex  vivo-activated  and  expanded  non-MHC-
restricted T cells. They can be prepared in large numbers
from peripheral blood mononuclear cells within 14-21
days, by appropriate addition of interferon-γ, interleukin-
2 and OKT3. CIK cells constitute a heterogeneous popu-
lation, including a subset of NKT cells that express both
CD3 and CD56 markers.
10-13 The antitumor effect of CIK
cells  was  demonstrated  particularly  in  lymphoma  cell
lines and leukemic blasts, both in vitro and in vivo,
14-16 but
these  cells  also  have  antitumor  activity  against  solid
tumors such as osteosarcoma, hepatocellular carcinoma
and glioblastoma.
17-19 Their cytotoxic effect is mediated
by  a  perforin/granzyme-dependent  mechanism.
20,21
Although their tumor recognition and killing properties
are not fully understood, these seem to be mediated in
part by NKG2D, an activating receptor on NK cells, and
the adhesion receptor leukocyte function associated anti-
gen-1 (LFA-1).
20,21 CIK cells also express CD94, part of the
NK  CD94/NKG2  family  receptors  with  activating  or
inhibitory  potential.
15 A  good  correlation  between  up-
regulation  of  NK-activating  C-type  lectin  NKG2C  and
NKG2E  receptors  and  CIK  cell  cytotoxicity  has  been
reported.
22
Remarkably, CIK cells showed only limited graft-ver-
sus-host effects in various mouse models.
23,24 Two phase
I clinical trials (one in patients with hepatocellular carci-
noma and the other in patients with Hodgkin’s disease or
non-Hodgkin’s lymphoma) showed significant improve-
ment in survival of patients after reinfusion of autolo-
gous CIK cells.
25,26 Another phase I clinical trial investi-
gated repeated administration of donor-derived CIK cells
in an allogeneic transplantation setting:
27 symptoms of an
acute  graft-versus-host  disease  (grade  I  and  II)  were
observed in 4/11 (36%) cases and complete responses in
3/11 (27%) cases. 
Based on their antitumor activity and already reported
low graft-versus-host disease potential, we investigated
whether  CIK  cells  generated  from  peripheral  blood
mononuclear cells from healthy donors show cytotoxic
potential against embryonic and alveolar rhabdomyosar-
coma cells. In addition, the molecular mechanisms medi-
ating their cytotoxic effect were investigated. As adop-
tive immunotherapy is associated with the risk of graft-
versus-host disease, we evaluated the expression of CD69
and  CD137  as  activation-induced  markers,  because
depletion of T cells expressing these antigens results in
selective removal of alloreactive T cells.
28-31
Design and Methods
Generation of cytokine-induced killer cells from 
peripheral blood mononuclear cells
Fifteen  to  twenty  milliliters  of  heparinized  peripheral  blood
from six healthy volunteers were collected after written informed
consent. Peripheral blood mononuclear cells were separated by
Ficoll density gradient centrifugation (Biocoll, Biochrom, Berlin,
Germany).
The freshly isolated peripheral blood mononuclear cells were
resuspended at a density of 3ﾥ10
6/mL in culture medium and incu-
bated  with  1000  U/mL  interferon-γ (Imukin,  Boehringer,
Ingelheim, Germany) at 37°C (day 0). On day 1 the concentration
of the cells was adjusted to 1ﾥ10
6/mL and 50 ng/mL of Orthoclone
monoclonal  OKT3  antibody  (Janssen-Cilag,  Neuss,  Germany)
together  with  500  U/mL  of  recombinant  human  interleukin-2
(Proleukin S, Novartis, Nuremberg, Germany) were added. Cell
numbers were assessed every 3 to 4 days and cell density was
adjusted to 1ﾥ10
6/mL by adding fresh culture medium and inter-
leukin-2 at a concentration of 500 U/mL. CIK cells were further
grown in RPMI 1640 supplemented with 10% fetal calf serum and
500 U/mL recombinant human interleukin-2, referred to as the
culture medium. The input cells were characterized phenotypical-
ly and functionally at day 0, and the expanded cells at days 7, 14
and 21.
Cell lines
Soft tissue sarcoma cell lines RMS13, Rh30, RH41 (alveolar
rhabdomyosarcoma), TE671, RD (embryonic rhabdomyosarco-
ma), RH1 (Ewing’s sarcoma) and erythroleukemia K562 were
obtained from DSMZ (Braunschweig, Germany). RH1 was orig-
inally classified as a rhabdomyosarcoma cell line but was recent-
ly reclassified when gene expression profiling revealed that it
expressed EWS-FLI1, a fusion transcript characteristic of tumors
of  the  family  of  Ewing’s  sarcoma  malignancies.  All  cell  lines
were maintained in culture according to instructions from the
DSMZ. 
Multiparameter flow cytometric analysis
To characterize the antigen profile of CIK and rhabdomyosarco-
ma cells, multiparameter flow ctyometric analysis was performed
following exposure of the cells to monoclonal mouse anti-human
antibodies  conjugated  to  fluorescein  isothiocyanate,  phycoery-
thrin, peridinin chlorophyll protein or allophycocyanin. The anti-
bodies used were CD1a, CD1b, CD1d, CD3, CD4, CD8, CD11a,
CD40,  CD45,  CD54,  CD56,  CD69,  CD94,  CD102,  CD137,
CD154, CD161, CD337, granzyme A, granzyme B, perforin (BD
Biosciences,  Heidelberg,  Germany),  TCRVʱ24,  TCRVb11
(Beckman  Coulter,  Krefeld,  Germany),  CD314,  MICA/B,  and
ULBP-2  (R&D  Systems,  Wiesbaden,  Germany).  Data  were
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Heidelberg,  Germany)  and  analyzed  with  CellQuest  and
CellQuest pro software (Becton Dickinson).
Europium release assay
The lytic potential of CIK cell cultures was assessed using a
europium release assay according to the manufacturer’s instruc-
tions. Target cells were incubated with BATDA reagent (Perkin
Elmer, Waltham, Massachusetts, USA) for 30 min at 37°C. After
extensive washing the target cells were resuspended in medium,
plated at a density of 5000 cells/well in a 96-well plate and effec-
tor cells were added at different effector to target (E:T) ratios. After
incubation for 2 h at 37°C, supernatant was harvested and incu-
bated with europium solution (Perkin Elmer) for 15 min under
continuous rotation. Europium and TDA-ligand form a highly flu-
orescent and stable chelate complex (EuTDA) that can be meas-
ured  in  a  time-resolved  fluorometer  (1420-018  Victor,  Perkin
Elmer).  Background,  spontaneous  and  maximal  release  were
measured in the medium, from target cells alone and from cells
following the addition of 5% Triton X (Sigma), respectively, and
calculated by means of the following formula: specific cytotoxici-
ty  (%)  =  100  x  (experimental  release  -  spontaneous
release)/(maximum  release  -  spontaneous  release)  and  sponta-
neous release (%) = (spontaneous release - background)/(maxi-
mum release -background).
Results
Ex vivo expansion and immunophenotyping 
of cytokine-induced killer cells
Using the protocol described above we were able to
expand CIK cells derived from peripheral blood mononu-
clear cells by 2.3-fold at day 7, 16.1-fold at day 14 and 22.7
fold at day 21 (Figure 1A). The majority of the cells had a
CD3
+CD56
– phenotype.  Remarkably,  the  proportion  of
NKT (CD3
+CD56
+) cells in the culture increased over time
from 4.82% at day 0 (range, 0.82-10.86%) to 9.36% at day
7 (range, 3.1-15.7%), 20.6% at day 14 (range, 9.1-32.9%)
and 30.9% at day 21 (range, 15.9-46.1%) (Figure 1B, C).
Expression of T and NK cell receptors 
on cytokine-induced killer cells
During cell culture the number of CD3
+CD56
+cells co-
expressing CD8 antigen increased from 63.5±7.4% on day
0  to  77.3±3.4%  on  day  21,  in  contrast  to  the
CD3
+CD56
+CD4
+ cell  subpopulation  which  decreased
continuously from 20±3.3% on day 0 to 5.3±1.3% on day
21 (Online Supplementary Figure S1A). The proportion of
CD3
+CD56
+ cells  co-expressing  TCRʱb was  highest  on
day 0 (77.3±6%) and remained fairly constant through to
day  21  (67.5±5.9%).  In  contrast,  the  number  of
CD3
+CD56
+ cells  co-expressing  TCRγδ increased  from
12.6±2.6%  on  day  0  to  19.9±5.1%  on  day  21  (Online
Supplementary Figure S1B). These cells did not, however,
express the invariant T-cell receptor which is usually com-
posed of TCRVʱ24 ʱ-chain and TCRVb11 b-chain, sug-
gesting that these NKT cells belong to type II NKT cells.
Most  of  the  CD3
+CD56
+ cells  (85.9±5.6%)  expressed
the activating NKG2D receptor (CD314) on day 0 and the
percentage of the cells expressing this antigen increased to
96±3% by day 21. On day 0, only 43.8±7.4% of NKT cells
expressed  the  natural  cytotoxicity  receptor  CD337
(NKp30), responsible for NK cell activation in the process
of natural cytotoxicity; by days 7 and 14 the number of
cells  positive  for  this  antigen  had  roughly  doubled
(81.7±5.9%)  although  by  day  21  the  number  had
decreased to the initial level (Online Supplementary Figure
S1C). The pattern of expression of killer inhibitory recep-
tors (CD94 and CD161) was more or less the same, with
an increase in the number of cells expressing these anti-
gens at day 7 and then a gradual decrease to the initial
expression levels (Online Supplementary Figure S1C).
Flow cytometric analysis of CIK cells demonstrated that
these  cells  represent  a  mixture  of  T  cells  with  naïve
CIK cells lyse rhabdomyosarcoma cells
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Figure 1. CIK cell expansion out
of peripheral blood mononuclear
cells  from  healthy  donors.  (A)
Freshly isolated peripheral blood
mononuclear  cells  from  six
healthy  donors  were  expanded
for 21 days according to the pro-
tocol described in the Design and
Methods section. (B) During cul-
ture CIK cells expanded and gave
rise to three main cell subsets: T
cells  (CD3
+CD56
-),  NKT  cells
(CD3
+CD56
+) and NK cells (CD3
-
CD56
+). Flow cytometric analysis
was performed on days 0, 7, 14
and  21  of  cell  culture.  (C)
Representative  flow  cytometric
data  of  the  CIK  cell  culture  on
days 0, 14 and 21.
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–),
effector memory (CD62L
–CD45RA
–) and effector memory
RA
+ (EMRA)  (CD62L
–CD45RA
+)  phenotypes  (Online
Supplementary Figure S1D).
Perforin, granzyme A and granzyme B expression
in cultures of cytokine-induced killer cells
To characterize the cytotoxic potential of CIK cells, we
evaluated their intracellular expression of effector mole-
cules.  Flow  cytometry  analysis  revealed  a  continuous
increased expression of granzyme A and granzyme B in
CIK cells throughout cell culture. The mean percentage of
CD3
+CD56
+CD8
+ cells expressing granzyme A increased
significantly from 49.8±11.7% on day 0 to 73.4±9.5% on
day 21, while the mean percentage of CD3
+CD56
+CD8
+
cells expressing granzyme B increased from 57.5±19.2%
on  day  0  to  74.1±0.6%  (Figure  2A).  In  contrast  to  the
increases of granzyme A and B, the intracellular expres-
sion  of  perforin  decreased  from  39.6±6.8%  (day  0)  to
2.9±1.1% (day 21) (Figure 2A).
Cytotoxic activity of cytokine-induced killer cells
against alveolar and embryonic rhabdomyosarcoma
The capacity of CIK cells to recognize and kill the stan-
dard target K562, alveolar rhabdomyosarcoma, embryon-
ic rhabdomyosarcoma and Ewing’s sarcoma cell lines was
evaluated by using a europium release-assay.
At an E:T ratio of 50:1 CIK cells specifically lysed K562
cells (68.2±4.1% at day 7, 37.7%±7.6% at day 14 and
70.5±8.3% at day 21) (data not shown). The lytic capacity
against the various rhabdomyosarcoma cell lines was less
than that against K562 cells. The maximal lytic capacity
against the Ewing’s sarcoma cell line, RH1, was detected
using CIK from day 7 of cell culture. At an E:T ratio of 50:1
these cells showed a specific lysis of 40%±8.3% (Figure
2B). Best results were achieved when using CIK from day
7 of cell culture against RMS13, and from day 14 against
RH41. At an E:T ratio of 50:1, a maximum of 35.1±13.8%
of RMS13 cells were lysed by day 7 CIK (Figure 2C), and
46.1±4.7% of RH41 cells were lysed by day 14 CIK cells
(Figure 2D).
Maximal cytotoxic activity against cells of the embryon-
ic rhabdomyosarcoma cell line TE671 was shown by day
7 CIK cells. At an E:T ratio of 50:1 such CIK cells lysed
35.6±7.83%  of  TE671  rhabdomyosarcoma  cells  (Figure
2E). Likewise, maximal cytotoxic activity against the other
embryonic  rhabdomyosarcoma  cell  line,  RD,  was  also
achieved by day 7 CIK. At an E:T ratio of 50:1, CIK cells
lysed 33.2%±3.1% of RD cells (Figure 2F).
Mechanisms of the cytotoxic activity of cytokine-induced
killer cells against rhabdomyosarcoma cell lines
Antibody-mediated masking of the NKG2D-receptor on
the surface of CIK cells led, in general, to their decreased
cytolytic activity as effector cells. For example, at an E:T
ratio of 50:1, the lytic capacity against the RH41 cell line,
which expresses very low levels of MICA/B but very high
levels  of  ULBP2  (Figure  3Aii,  iii),  decreased  from
25.2±2.6% to 13.7±2.8% (P<0.001) (Figure 3Ai). As a con-
sequence of this blocking, the cytotoxicity of CIK cells
against  embryonic  rhabdomyosarcoma  TE671  cells,
which  expresses  almost  no  MICA/B  antigens,  but  very
high levels of ULBP-2 (Figure 3Bii, iii), decreased dramati-
cally. Hence, the differences between the cytotoxic poten-
tial  of  CIK  cells  with  blocked  NKG2D  receptor  and
unblocked CIK cells were highly significant at E:T ratios of
100:1  (P<0.008),  50:1  (P<0.003),  25:1  (P<0.004),  12.5:1
(P<0.01) and 6.25:1 (P<0.006) (Figure 3Bi).
The non-classical MHC molecules MICA/B and ULBP-2
are target molecules for the NKG2D receptor. Blocking
each of these molecules separately on rhabdomyosarcoma
cells led to a decrease in cytolytic activity of the effector
cells (data not shown), while blocking both target cell lig-
ands,  which  are  highly  expressed  by  the  RH1  cell  line
S. Kuci et al.
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Figure 2. Cytotoxic activity
of  in  vitro-generated  CIK
cells from healthy donors
against  rhabdomyosarco-
ma  cell  lines.  (A)
Intracellular expression of
effector  molecules  in  CIK
cells.  A  continuous
increase  of  granzyme  A
and  B  and  simultaneous
decrease  of  perforin  over
21 days of cell culture was
observed.  Data  from  five
experiments are shown as
mean  ±  SEM.  Cytotoxic
activity of CIK cells gener-
ated  from  healthy  blood
donors against the Ewing’s
sarcoma cell line RH1 (B),
alveolar  rhabdomyosarco-
ma  cell  lines  RMS13  (C)
and RH41 (D) as well as
embryonic  rhabdomyosar-
coma cell lines TE671 (E)
and RD (F) was assessed
by  europium-release
assays.  Results  represent
data from three separate
experiments  and  are
shown as mean ± SEM for
each cell line.
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Day 21(Figure  3Cii,  iii),  induced  a  further  impairment  in  the
killing efficiency of CIK cells such that the killing efficien-
cy  of  CIK  cells  against  this  target  was  significantly
decreased at E:T ratios of 100:1 (P<0.02), 50:1 (P<0.04),
25:1 (P<0.03), and 12.5:1 (P<0.02) but not at an E:T ratio
of  6.25:1.  (Figure  3Ci).  Inhibition  of  CD11a,  CD3  or
TCRʱb on the cell surface of CIK effector cells by means
of blocking monoclonal antibodies did not influence the
cytotoxic effect of the CIK cells (data not shown).
Cytokine-induced killer cells and their alloreactivity
potential
The lytic capacity of CIK cells against allogeneic periph-
eral blood mononuclear cells was analyzed on days 7, 14
and 21 of cell culture. There were no major differences in
the specific cell lysis at the different E:T ratios (Figure 4A).
The  expression  of  CD69  and  CD137,  cell  activation-
induced markers, was related to low reactivity of CIK cells
against allogeneic peripheral blood mononuclear cells. We
found that the expression of CD69 by CD3
+CD56
+CD8
+
cells decreased from 28.9±9.8% on day 0 to 3.2±1.1% on
day 21, whereas CD137 antigen expression showed an
increase on day 7 and then fell to the low initial expression
levels (0.8±0.1%) (Figure 4B).
Apoptosis induced by tumor necrosis factor-related
apoptosis-inducing ligand and caspase 3 
In addition to the granule-dependent exocytosis path-
way demonstrated by CIK cells, we investigated whether
CIK cells use an additional mechanism to induce apopto-
sis of target rhabdomyosarcoma cells. After co-incubation
of  CIK  cells  with  rhabdomyosarcoma  cells  for  4  h  we
observed the expression of caspase-3 by the latter as a sign
of ongoing apoptosis. CIK cells were visualized by stain-
ing them with anti-CD45 antibody (Figure 4C), because
rhabdomyosarcoma cells lack CD45 antigen. In order to
determine whether caspase-3 is activated by tumor necro-
sis factor-related apoptosis-inducing ligand (TRAIL) as a
result of cell-cell contact, we counterstained CIK cells with
monoclonal antibody against this molecule. Analysis by
fluorescence microscopy revealed the presence of TRAIL
molecules on the surface of CIK cells (red fluorescence)
(Figure  4D).  In  addition,  blocking  TRAIL  receptors  on
rhabdomyosarcoma cells led to a significant reduction of
the cytotoxicity of CIK cells against the embryonic rhab-
domyosarcoma cell line TE671 at E:T ratios of 100:1 (P<
0.001), 50:1 (P<0.005), 25:1 (P<0.01), and 12.5:1 (P<0.05),
but not at the ratio of 6.25:1 (Figure 4F). In contrast, block-
ing TRAIL receptors on the alveolar rhabdomyosarcoma
cell line RMS13 did not affect the cytotoxic activity of CIK
cells against these malignant cells (Figure 4E).
Discussion
In the present study, we investigated the in vitro cytotox-
ic potential of CIK cells against embryonic and alveolar
rhabdomyosarcoma cell lines as well as against a Ewing’s
sarcoma  cell  line  (RH1).  Our  results  demonstrated  that
CIK  cells  use  a  TCR-independent  mechanism  for  their
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Figure  3. CIK-cell  cytotoxicity  after  anti-
body-mediated masking of NKG2D recep-
tor  or  NKG2D  ligands.  (A)  Cytotoxicity
against  the  alveolar  rhabdomyosarcoma
cell line RH41 was measured after block-
ing NKG2D receptor by means of a mono-
clonal antibody on CIK cells (n=4). These
cells  express  low  levels  of  MICA/B  and
high levels of ULBP2 (Aii,iii). Blocking the
NKG2D  receptor  significantly  decreased
the cytotoxicity of CIK cells against RH41
rhabdomyosarcoma cells at ratios of 100:1
(P<0.02),  50:1  (P<0.001),  and  25:1
(P<0.009)  (Ai).  (B)  Antibody-mediated
masking of NKG2D receptor on CIK cells
(n=4) significantly decreased their cytotox-
ic  potential  against  embryonic  rhab-
domyosarcoma TE671 cell line at all ratios
e.i. 100:1 (P<0.008), 50:1 (P<0.003), 25:1
(P<0.004),  12.5:1  (P<0.01)  and  6.25:1
(P<0.006) (Bi). This cell line expresses low
levels of MICA/B and high levels of ULBP2
(Bii,iii). (C) To verify whether non-classical
MHC molecules MIC A/B and ULBP2 repre-
sent the main target on rhabdomyosarco-
ma cells recognized by NKG2D of CIK cells
these molecules were blocked on the RH1
cell line (n=3) that expresses high levels of
both  molecules  (Cii,iii).  Blocking  both  of
these molecules on the RH1 cell line signif-
icantly decreased the killing efficiency of
CIK cells against this target at E:T ratios of
100:1  (P<0.02),  50:1  (P<0.04),  25:1
(P<0.03), and 12.5:1 (P<0.02) but not at
an E:T ratio of 6.25:1. (Figure 4Ci). Colored
histograms represent the isotype control,
whereas  white  histograms  represent  the
percentage  of  rhabdomyosarcoma  cell
lines  positive  for  MICA/B  or  ULBP2  anti-
gens.
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Figure 4. Alloreactivity of CIK cells and
their apoptosis-inducing mechanisms in
target cells. (A) Alloreactivity of CIK cells
was evaluated against allogeneic periph-
eral blood mononuclear cells as targets
at different E:T ratios by means of the
europium  release  assay.  Results  repre-
sent data from separate experiments for
each measurement at days 7, 14 and 21
(n=10). (B) Alloreactivity of CIK cells was
evaluated  by  expression  of  activating
markers  CD137  and  CD69  during  cell
culture  for  21  days.  Results  represent
data from five experiments with five dif-
ferent donors and are shown as mean ±
SEM.  (C)  Expression  of  caspase-3  by
rhabdomyosarcoma  cells  (red  fluores-
cence), as a main caspase responsible
for the execution of apoptosis, was found
4  h  after  co-incubation  with  CIK  cells
(green  fluorescence)  (magnification:
100x). (D) CIK cells (green fluorescence)
express  TRAIL  (red  fluorescence)  after
co-incubation  with  rhabdomyosarcoma
cells (not stained nuclei) (magnification:
200x). (E) Blocking of TRAIL receptors on
alveolar RMS cell line RMS13 (n=3), did
not  affect  the  cytotoxic  activity  of  CIK
cells against these cells. (F) Blocking of
TRAIL receptors on the embryonic rhab-
domyosarcoma cell line TE671 (n=3) led
to  significantly  reduced  cytotoxicity  of
CIK  cells  at  E:T  ratios  of  100:1
(P<0.001),  50:1  (P<0.005),  25:1
(P<0.01),  and  12.5:1  (P<0.05)  com-
pared to the cytotoxicity of CIK against
unblocked TE671 cells. 
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cytotoxic effect, as previously reported.
13 We found that
despite an increased TCRʱb expression by CIK cells, the
cytotoxic effect of day 7 and 21 CIK cells decreased. In
addition, blocking TCRʱb did not cause a decrease of lytic
capacity. In the next step, we tried to determine whether
CD11a  (LFA-1)  or  NKG2D  expressed  on  CIK  cells  or
CD1d on rhabdomyosarcoma cells, as a target molecule,
are involved in cytotoxicity against rhabdomyosarcoma
cell  lines  as  described  for  other  tumor  cells.
20,21 Neither
blocking CD11a on CIK cells nor blocking CD1d on rhab-
domyosarcoma cells showed an effect on the cytotoxicity
of  the  CIK  cells  (data  not  shown).  However,  blocking
NKG2D receptor on CIK effector cells or NKG2D ligands
on rhabdomyosarcoma target cells did lead to a significant
decrease  in  cytotoxicity.  Despite  antibody-mediated
masking of NKG2D receptor on the surface of CIK cells,
these cells were still effective in killing rhabdomyosarco-
ma cells, suggesting that CIK cell-mediated cytotoxicity is
only partially mediated by this activating receptor. 
Activating natural cytotoxicity receptors such as NKp30,
NKp44 and NKp46 have been considered to be specific
NK receptors, playing an important role in NK-cell medi-
ated  cytotoxicity  against  tumor  cells.
32,33 The  level  of
expression  of  the  natural  cytotoxicity  receptor  CD337
(NKp30) on CIK cells correlated very well with the cells’
cytotoxic potential against rhabdomyosarcoma cells. On
day  7  and  14  the  number  of  CIK  cells  expressing  this
receptor increased, while on day 21 a decrease to the ini-
tial levels was observed. 
On  the  other  hand,  three  main  groups  of  inhibitory
receptors and their ligands are described for NK cells: (i)
receptors of the KIR family (KIR2DL and KIR3DL), (ii) C-
type lectin receptors such as CD94/NKG2A, and (iii) the
Ig-like transcripts/CD85.
34-36 As NKp44 was described on
activated γδ T cells,
37 and the activating NK heterodimers
CD94/NKG2C and CD94/NKG2E are found on the sur-
face of CIK cells, we investigated whether inhibitory NK
receptors such as CD161 might also be expressed on CIK
cells. We observed an increase of CD161 expression on
day 7 of CIK cell culture and then decreases on days 14
and 21. To our knowledge, this is the first time the pres-
ence of CD161 on CIK cells has been described. Whether
rhabdomyosarcoma  cells  upregulate  LLT1  (CD161  lig-
and)
38 through  autocrine  production  of  transforming
growth factor-b
39 in order to evade the antitumor activity
of  CIK  cells  remains  to  be  elucidated  in  future  experi-
ments.  In  addition,  CD94,  a  part  of  the  C-type  lectin
receptor  CD94/NKG2,  showed  a  pattern  of  expression
similar to that of CD161 antigen on the surface of the
CD3
+CD56
+ subset of cells. It has been reported that up-
regulation of activating CD94/NKG2C and CD94/NKG2E
receptors in the CIK cell population correlates very well
with observed cytotoxicity.
22 However, according to our
results expression of killer inhibitory receptors CD94 and
CD161 seemed to play a less important role in mediating
the cytotoxicity of CIK cells against rhabdomyosarcoma
cells, because their expression did not directly correlate
with the potential of CIK cells to kill the rhabdomyosar-
coma cells.
Franceschetti et al.
40 reported that CIK cells are terminal-
ly activated cytotoxic T-EMRA lymphocytes. Flow cyto-
metric analysis of CIK cells has demonstrated that these
cells  represent  a  mixture  of  T  cells  with  naïve
(CD62L
+CD45RA
+),  central  memory  (CD62L
+CD45RA
–),
effector memory (CD62L
–CD45RA
–) and effector memory
RA
+ (EMRA) (CD62L
–CD45RA
+) phenotypes. In our ana-
lyzed samples of CIK cells the largest proportion of T cells
had an effector memory phenotype, followed by T cellswith a central memory phenotype and naïve T cells, while
the smallest proportion of T cells had an EMRA phenotype. 
To further study the contribution of effector molecules
to the cytotoxic potential of CIK cells, we evaluated the
time-line of perforin/granzyme expression in CIK cell cul-
ture over 21 days. Remarkably, there was a continuous
increase  of  granzyme  A  and  granzyme  B  expression
throughout the 21 days of cell culture, while at the same
time the number of CD3
+CD56
+ cells expressing perforin
decreased.  Perforin,  granzyme  A  and  granzyme  B  are
described as essential molecules for CIK cell cytotoxicity,
20
with  perforin  being  absolutely  necessary  to  deliver  the
granzymes  to  the  cytoplasm  of  target  cells.
41 Based  on
these results we, therefore, assume that the decrease in
cytotoxicity of CIK cells against rhabdomyosarcoma cells
over  the  time  in  culture  may  be  a  consequence  of
decreased expression of perforin by day 21 CIK cells. In
order to increase perforin expression and consequently the
cytotoxic effect of the CIK cells, we suggest modifying the
expansion protocol of the CIK cells by adding interleukin-
15, given that other studies showed that perforin expres-
sion  and  cytotoxicity  of  NK  and  lymphokine  activated
killer cell were significantly higher when cells were cul-
tured with interleukin-15.
42
As previously reported, the antitumor effect of CIK cells
is not mediated through a Fas-Fas ligand interaction.
13,24
We,  therefore,  investigated  whether  CIK  cells  use  the
TRAIL-mediated  caspase-3  activation  pathway.
Immunocytochemical analysis of CIK cells co-incubated
with rhabdomyosarcoma cells indicated that CIK cells do
express TRAIL molecules which may ultimately lead to
activation of caspase-3 in rhabdomyosarcoma cells, as a
main caspase responsible for the execution of apoptosis.
Remarkably, blocking TRAIL receptors on rhabdomyosar-
coma cell lines demonstrated that the embryonic rhab-
domyosarcoma  TE671  cell  line,  but  not  the  alveolar
RMS13  cell  line,  is  apparently  highly  sensitive  to  the
TRAIL-induced apoptosis pathway induced by CIK cells.
To our knowledge, this is the first direct evidence that CIK
cells use this apoptosis-inducing pathway in their antitu-
mor activity.
To be suitable cells for transplantation and not to induce
graft-versus-host disease, CIK cells should not be alloreac-
tive. We, therefore, examined whether CIK cells express
cell activation-induced antigens CD69 and CD137 during
culture. In our study, we observed low levels of CD69 and
CD137 expression by CIK cells. In addition, the CIK cells
showed  a  low  level  of  cytotoxicity  against  allogeneic
peripheral blood mononuclear cells as target cells. Despite
this low alloreactivity in vitro, in the first clinical studies
some patients infused with CIK cells developed mild graft-
versus-host disease (grade I and II).
27
We conclude that CIK cells can be easily isolated and
expanded from peripheral blood mononuclear cells in bulk
quantities. Bearing in mind their low level of alloreactivi-
ty and efficient antitumor activity, CIK cells may be used
as a novel therapeutic strategy in the treatment of patients
with rhabdomyosarcoma after allogeneic stem cell trans-
plantation.
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